Incendia Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$13.3M
- Investors
-
11
Incendia Therapeutics General Information
Description
Operator of a novel therapeutics company intended to invent a class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The company designs a portfolio of drug candidates that interplay between cancer cells and their surrounding microenvironment, which is relevant in drug development to build barriers that shield the immune system from attacks, and one approach breaks these barriers to overcome recalcitrant cancers that are based on rigorous, ground-breaking research, enabling doctors to treat the right patients at the right time.
Contact Information
Website
www.incendiatx.comCorporate Office
- 40 Guest Street
- Boston, MA 02135
- United States
Corporate Office
- 40 Guest Street
- Boston, MA 02135
- United States
Incendia Therapeutics Timeline
Incendia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 09-Sep-2025 | $13.3M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series A1) | 01-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 13-Aug-2021 | $65M | $65M | Completed | Clinical Trials - Phase 1 |
Incendia Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 60,597 | $0.000100 | $3.37 | $3.37 | 1x | $3.37 | 0.14% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Incendia Therapeutics Comparisons
Industry
Financing
Details
Incendia Therapeutics Competitors (2)
One of Incendia Therapeutics’s 2 competitors is Celldex, a Formerly VC-backed company based in Hampton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celldex | Formerly VC-backed | Hampton, NJ | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA |
Incendia Therapeutics Patents
Incendia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023379591-A1 | Methods of treating cancer using anti-ddr1 antibodies | Pending | 16-Nov-2022 | ||
| EP-4619441-A1 | Methods of treating cancer using anti-ddr1 antibodies | Pending | 16-Nov-2022 | ||
| US-20260184795-A1 | Methods of treating cancer using anti-ddr1 antibodies | Pending | 16-Nov-2022 | ||
| WO-2024107899-A1 | Methods of treating cancer using anti-ddr1 antibodies | Inactive | 16-Nov-2022 | ||
| AU-2023379587-A1 | Methods of treating cancer using anti-ddr1 antibodies and immune checkpoint inhibitors | Pending | 16-Nov-2022 | C07K16/2851 |
Incendia Therapeutics Signals
Incendia Therapeutics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| abrdn Healthcare Investors | Hedge Fund | Minority | ||
| Aberdeen Investments (Scotland) | Asset Manager | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Breakout Ventures | Venture Capital | Minority | ||
| Creacion Ventures | Venture Capital | Minority |
Incendia Therapeutics FAQs
-
When was Incendia Therapeutics founded?
Incendia Therapeutics was founded in 2019.
-
Where is Incendia Therapeutics headquartered?
Incendia Therapeutics is headquartered in Boston, MA.
-
What is the size of Incendia Therapeutics?
Incendia Therapeutics has 19 total employees.
-
What industry is Incendia Therapeutics in?
Incendia Therapeutics’s primary industry is Drug Discovery.
-
Is Incendia Therapeutics a private or public company?
Incendia Therapeutics is a Private company.
-
What is Incendia Therapeutics’s current revenue?
The current revenue for Incendia Therapeutics is .
-
How much funding has Incendia Therapeutics raised over time?
Incendia Therapeutics has raised $78.3M.
-
Who are Incendia Therapeutics’s investors?
abrdn Healthcare Investors, Aberdeen Investments (Scotland), Alexandria Venture Investments, Breakout Ventures, and Creacion Ventures are 5 of 11 investors who have invested in Incendia Therapeutics.
-
Who are Incendia Therapeutics’s competitors?
Celldex and AVEO Oncology are competitors of Incendia Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process